Journal
MOLECULAR CANCER RESEARCH
Volume 11, Issue 3, Pages 240-250Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-12-0432
Keywords
-
Categories
Funding
- NIH [R01-CA142776, P50-CA83638-7951, 5K12HD000849]
- Department of Defense [W81XWH-10-1-0082]
- Ovarian Cancer Research Fund
- China Scholarship Council
Ask authors/readers for more resources
The heterochronic gene let-7 serves as a tumor suppressor microRNA by targeting various oncogenic pathways in cancer cells. Considerable evidence indicates that reduced expression of let-7 might be associated with poor clinical outcome in patients with cancer. Here, we report that the expression levels of three let-7 family members, let-7a, let-7b, and let-7g, were significantly decreased in the patients with breast cancer with lymph node metastasis compared with those without lymph node metastasis. Enforced expression of let-7b significantly inhibits breast cancer cell motility and affects actin dynamics. Using bioinformatic and experimental approaches, four genes in the actin cytoskeleton pathway, including PAK1, DIAPH2, RDX, and ITGB8, were identified as let-7 direct targets. Blocking the expression of PAK1, DIAPH2, and RDX significantly inhibits breast cancer cell migration induced by let-7b repression. Our results indicate that reconstitution of let-7 expression in tumor cells could provide a novel therapeutic strategy for the treatment of metastatic disease. Mol Cancer Res; 11(3); 240-50. (C)2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available